Calendar Opportunities Companies Compare Analytics Learn Watchlist

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Loading market movers...

Free biotech catalyst calendar with AI-powered predictions. Track FDA decisions, PDUFA dates, clinical trial results, and Phase 3 readouts. Real-time alerts for biotech investors.

Quick Links

This Week's Catalysts
Full Calendar
Catalyst Types
Search Companies
Biotech Glossary
Embed Widget

Legal

About
ML Track Record
Privacy
Terms

Data Sources

ClinicalTrials.gov
SEC EDGAR
FDA

⚠️ Not Financial Advice (NFA)

CatalystAlert provides data aggregation and analysis tools only. All probability scores and predictions are based on historical data and are NOT guarantees of future results. Past performance does not indicate future success. We are not responsible for the accuracy of third-party data sources. Always consult a qualified financial advisor before making investment decisions.

© 2025 CatalystAlert. All rights reserved.

Data may be delayed or incomplete. Use at your own risk.

fruquintinib+sintilimab - Phase 3 | HCM Pipeline | CatalystAlert

fruquintinib+sintilimab

Phase 3

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Advanced Renal Cell Carcinoma

Clinical Trial

Last updated: 12/13/2025

Developer

HCM

Hutchmed

Healthcare•North America•NASDAQ

Related Pipeline

HMPL-306 RegimenPhase 3

Acute Myeloid Leukemia

Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and GemcitabinePhase 3

Metastatic Pancreatic Cancer

fruquintinibPhase 3

Advanced Endometrial Cancer

HMPL-453Phase 2

Advanced Intrahepatic Cholangiocarcinoma

HMPL-689Phase 2

Relapsed/Refractory Lymphoma

View full pipeline